FASLG and Thrombocytopenia: In an open-label, prospective pilot study of rituximab in 19 patients with primary APS, although the decrease of aPL titers could not be observed, the rituximab was found to be effective in controlling noncriteria manifestations such as skin ulcers, nephropathy, cognitive dysfunction, and thrombocytopenia.